About Frontier Biotechnologies Inc. Company

The company was founded in 2013 and is committed to the research, development, production and sale of innovative drugs for unmet major clinical needs. The company is a pioneer enterprise in the field of innovative antiviral drug research. In particular, it has international competitiveness in the long-term treatment of HIV and immunotherapy segments, and has formed an international business pattern based in China and facing the world. The company is mainly engaged in R&D, production and sales of antiviral and musculoskeletal pain treatment drugs. The company's main products: Iconin, an innovative anti-HIV drug, small nucleic acid drug products, Osteoporosis treatment product FB4001, hot melt adhesive patch FB3002 for musculoskeletal joint pain, and other analgesic hot melt adhesive products. Corporate honors: “24th China Patent Gold Award” and “First Jiangsu Patent Award Excellence Award”. The company won the honorary title of “Jiangsu Specialized and New Small and Medium Enterprises”, “China's Top 30 Innovative Small Molecule Pharmaceutical Enterprises of the Year”, “2022 Biotechnology Innovation Award”, “2022 Investment Pioneer Award”, “2022 China Biomedical Industry Value List Top 10 Most Growing Small Molecule Innovative Drug Companies”; in 2022, it won the honorary title of “2022 Investment Pioneer Award”, 2018 China's Top Ten Medical Science and Technology News, 2018 Innovative Drugs Innovative enterprises, 2016 Jiangsu Double Innovation Team, Key Overseas Chinese Entrepreneurship Teams, Outstanding Enterprises in the 6th China Innovation and Entrepreneurship Competition, “2024 Jiangsu Health Industry Research Association Member Units”, etc.